JeffreyBradfordLowMDMBA
Other MD/DO • San Francisco, CAPrincipal, Novo Growth | Life Sciences Investor
Dr. Low is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
501 2nd Street
#300
San Francisco, CA 94107
Clinical Expertise
- Venture Capital
Education & Training
Yale School of MedicineClass of 2015
Harvard Business SchoolMBA- Harvard UniversityAB, Molecular and Cellular Biology
Awards, Honors, & Recognition
- Forbes 30 under 30 in Venture Capital Forbes, 2019
Publications & Presentations
PubMed
- 63 citationsComplications associated with the use of the recombinant human bone morphogenetic proteins for posterior interbody fusions of the lumbar spine.Jesse Chrastil, Jeffrey B. Low, Peter G. Whang, Alpesh A. Patel
Spine. 2013-07-15 - 117 citationsRv3615c is a highly immunodominant RD1 (Region of Difference 1)-dependent secreted antigen specific for Mycobacterium tuberculosis infectionKerry A. Millington, Sarah M. Fortune, Jeffrey B. Low, Alejandra Garces, Suzanne M. Hingley-Wilson
Proceedings of the National Academy of Sciences of the United States of America. 2011-04-05 - 4 citationsProDisc-L learning curve: 24-Month clinical and radiographic outcomes in 44 consecutive cases.Jeffrey B. Low, Jerry Y. Du, Kai Zhang, James J. Yue
International Journal of Spine Surgery. 2012-12-01
Press Mentions
30 Under 30 Venture Capital 2019: These Up-and-Coming Investors Are Changing the Face of VCNovember 14th, 2018
External Links
- Websitehttp://jeffreylow.com
- a16z articleshttps://a16z.com/author/jeffrey-low/
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
